Maria E Nunez

20120244209, Sep 27, 2012

Mar 2, 2012

13/410811

Jack A. Roth - Houston TX, US
David Stewart - Ottawa, CA
Charles Lu - Houston TX, US
Ignacio I. Wistuba - Houston TX, US
Shaoyu Yan - Pearland TX, US
Maria I. Nunez - Houston TX, US

A61K 31/7088
C12Q 1/06
A61N 5/10
A61K 48/00
A61P 35/00
A61K 9/127
C12Q 1/68
C12Q 1/48

424450, 514 44 R, 435 61, 435 39, 435 15, 600 1

A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.

20160310569, Oct 27, 2016

Jul 11, 2016

15/207149

- Austin TX, US
David STEWART - Ottawa, CA
Charles LU - Houston TX, US
Ignacio I. WISTUBA - Houston TX, US
Shaoyu YAN - Pearland TX, US
Maria I. NUNEZ - Houston TX, US

Board of Regents, The University of Texas System - Austin TX

A61K 38/17
A61K 48/00
A61K 39/395
A61K 45/06
A61K 31/517
A61K 31/7135
C07K 16/30
A61K 9/127
C07K 16/28

A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.

20150297631, Oct 22, 2015

Apr 24, 2015

14/696081

- Austin TX, US
David STEWART - Ottawa, CA
Charles LU - Houston TX, US
Ignacio I. WISTUBA - Houston TX, US
Shaoyu YAN - Pearland TX, US
Maria I. NUNEZ - Houston TX, US

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

A61K 31/7135
A61K 39/395
A61K 9/127
A61K 45/06
A61K 31/7088
A61K 31/517

A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.

20140377339, Dec 25, 2014

Sep 8, 2014

14/480341

- Austin TX, US
David STEWART - Ottawa, CA
Charles LU - Houston TX, US
Ignacio I. WISTUBA - Houston TX, US
Shaoyu YAN - Pearland TX, US
Maria I. NUNEZ - Houston TX, US

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

A61K 9/127
A61K 31/517
C07K 14/47
A61K 38/17

424450, 514 44 R, 514 189, 5142664

A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.